Debate over pembrolizumab dosing gives rise…

Sahar van Waalwijk

Oct 16

"You may wonder why most dose optimisation and de-escalation studies come from the Netherlands"

2 Comments

Med Student's Substack

Oct 16Liked by Sahar van Waalwijk

Very helpful. No wonder the US is highest spend and mediocre results

Expand full comment

Julia’s Substack

Oct 23Liked by Sahar van Waalwijk

Really interesting information. Try

Expand full comment

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts